Comparative 2-D Tumor Analysis in Familial Gliomas
Completed
- Conditions
- Malignant Glioma
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 5
- Registration Number
- NCT00125710
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy
Completed
- Conditions
- Malignant Glioma
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 49
- Registration Number
- NCT00125697
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Sublingual Methadone for the Management of Cancer Breakthrough Pain
Phase 1
Completed
- Conditions
- CancerPain
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT00125294
Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer
Completed
- Conditions
- Cervix Cancer
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 5
- Registration Number
- NCT00124423
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation
Completed
- Conditions
- Prostate CancerOsteoporosis
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 100
- Registration Number
- NCT00124410
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Frequency of Portal Images Required to Enhance Quality Assurance for Breast Cancer Patients Treated With Radiotherapy
Withdrawn
- Conditions
- Breast Cancer
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Registration Number
- NCT00123812
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
Phase 2
Completed
- Conditions
- Ovarian NeoplasmsSarcomaMultiple MyelomaTesticular NeoplasmsKidney Neoplasms
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 1075
- Registration Number
- NCT00123773
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Neoplasms
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 23
- Registration Number
- NCT00123747
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection
Phase 2
Terminated
- Conditions
- Breast Neoplasms
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 199
- Registration Number
- NCT00123799
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
Phase 2
Completed
- Conditions
- LymphomaBrain NeoplasmsLung NeoplasmsThyroid NeoplasmsColorectal Neoplasms
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10838
- Registration Number
- NCT00123760
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Β© Copyright 2025. All Rights Reserved by MedPath